about
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules,...
Read More
20.12
-0.20
(-0.98%)
124.0K
XNAS Volume
XNAS 08 Aug, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Pharvaris NV is on 14 Aug 2025 for the purpose of Pharvaris NV Second Quarter Earnings Results for 2025
See details
Not Eligible
Expensive Valuation
Technically Neutral
Pharvaris NV Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..